{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-049645","form_type":"8-K","ticker":"ALBT","cik":"0001630212","company_name":"Avalon GloboCare Corp.","filed_at":"2023-06-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.739454+00:00","generated_at":"2026-06-13T22:47:56.468556+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Avalon GloboCare enters $3.5M ATM offering, reports Lab Services MSO financials","bullets":["Entered ATM sales agreement with Roth Capital for up to $3.5M of common stock; 3% commission.","Owns 40% of Lab Services MSO (Costa Mesa, CA); 2022 revenue $14.7M, net income $6.3M.","Suspended cellular therapy R&D to focus on laboratory rollup and KetoAir commercialization.","KetoAir breathalyzer (FDA Class I) detects acetone; exclusive distribution rights in NA, SA, EU, UK.","Lab Services MSO completed over 600,000 tests since inception; state-of-the-art facility."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-049645","json":"https://secwatch.observer/filing/0001213900-23-049645.json","markdown":"https://secwatch.observer/filing/0001213900-23-049645.md","text":"https://secwatch.observer/filing/0001213900-23-049645.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630212/000121390023049645/0001213900-23-049645-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630212/000121390023049645/ea180444-8k_avalon.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T22:47:56.468556+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6f0ea3ca39804e5eac85b1f4f9b25f4798b5ba3f","claim":"Avalon GloboCare Corp. entered into Sales Agreement with Roth Capital Partners, LLC valued at up to $3,500,000 (effective 2023-06-16).","evidence_excerpt":"On June 16, 2023, Avalon GloboCare Corp. (the “Company”) entered into that certain sales agreement (the “Sales Agreement”) with Roth Capital Partners, LLC (“Roth”), as sales agent, pursuant to which the Company may issue and sell, from time to time, through Roth, shares of its common stock, par value $0.0001 per share (the “Common Stock”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630212/000121390023049645/0001213900-23-049645-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"atm program"},{"label":"Counterparty","value":"Roth Capital Partners, LLC"},{"label":"Value","value":"up to $3,500,000"},{"label":"Effective","value":"2023-06-16"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}